SUPNNasdaqPharmaceutical PreparationsFiscal year ends December 31
SUPERNUS PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$39.84+1.96 (+5.17%)
Close on Oct 19, 2026
- Market cap
- $2.31B
- P/E (TTM)
- –
- Dividend yield
- –
SUPERNUS PHARMACEUTICALS, INC. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product sales | $643.02M | $635.30M | $626.54M | $634.92M | $636.68M | $641.22M | $637.70M | $627.32M | $606.02M | $571.82M | $573.93M | $581.70M | 77.4% | +1.0% |
| Qelbree | $329.44M | $317.75M | $304.65M | $298.12M | $279.07M | $260.92M | $241.27M | $213.21M | $187.93M | $159.51M | $140.19M | $117.45M | 39.7% | +18.1% |
| GOCOVRI | $152.25M | $151.38M | $146.82M | $145.10M | $139.91M | $134.95M | $130.82M | $125.91M | $123.14M | $120.19M | $119.64M | $116.89M | 18.3% | +8.8% |
| Collaboration revenue (ZURZUVAE) | $115.99M | $80.64M | $53.00M | $20.16M | $0 | – | $0 | – | – | – | – | – | 14.0% | – |
| Royalty, licensing, and other revenues | $71.43M | $60.89M | $39.42M | $26.46M | $28.45M | $26.77M | $24.12M | $24.65M | $24.14M | $25.58M | $33.59M | – | 8.6% | +151.1% |
| ONAPGO | $37.57M | $25.63M | $17.25M | $8.41M | $1.60M | $0 | $0 | – | – | – | – | – | 4.5% | +2242.3% |
| Trokendi XR | $36.32M | $39.10M | $42.42M | $48.85M | $54.12M | $60.01M | $63.20M | $68.00M | $73.30M | $75.54M | $94.34M | $131.92M | 4.4% | -32.9% |
| Oxtellar XR | $35.07M | $37.92M | $40.70M | $47.05M | $64.84M | $82.72M | $99.46M | $117.31M | $117.15M | $111.43M | $113.40M | $109.70M | 4.2% | -45.9% |
| APOKYN | $34.03M | $40.52M | $47.77M | $58.30M | $67.78M | $72.25M | $73.93M | $72.57M | $74.21M | $74.52M | $75.08M | $74.47M | 4.1% | -49.8% |
| Other | $18.35M | $23.00M | $26.91M | $29.09M | $29.36M | $30.37M | $29.01M | $30.33M | $30.29M | $30.63M | $31.28M | $31.26M | 2.2% | -37.5% |
| Royalty and licensing revenues | – | – | – | – | – | – | – | – | – | – | $33.59M | $28.84M | – | – |
By region
From the segment and revenue-disaggregation notes of Supernus Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.